Phase II trial of S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neck
- Conditions
- Recurrent/metastatic squamous cell carcinoma of the head and neck
- Registration Number
- JPRN-UMIN000015123
- Lead Sponsor
- Hokkaido University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 21
Not provided
(1)History of severe hypersensitivity (2)Active infection (3)Severe and uncontrolled complication(severe heart failure, cerebrovascular disease, pulmonary fibrosis, renal failure, liver failure, active peptic ulcer, uncontrolled diabetes mellitus, uncontrolled hypertention, etc.) (4)Uncontrolled pleural, pericardial effusion or ascites (5)Symptomatic brain metastasis (6)Simultaneous or metachronous double cancers within the past 5 years other than skin cancer (malignant melanoma is excluded), carcinoma in situ of uterine cervix and mucosal carcinoma of digestive tract (7)Receiving flucytocine (8)HBs Ag positive (9)Pregnant or lactating women or women of childbearing potential and men in hope of the pregnancy of the partner (10)Unstable psychiatric disease (11)Surgery or radiotherapy within 4 weeks (12)Decision of ineligibility by a physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method